Innovative mishonga yechirwere chekufamba

Musi waChivabvu 15, Vanda Pharmaceuticals, kambani yeUS biopharmaceutical, yakazivisa kuti yechipiri Chikamu chechitatu chekudzidza nezvemushonga wayo mutsva weTradipitant (tradipitant) wekurapa chirwere chekufamba (kunyanya chirwere chekufamba) chakawana mhedzisiro.
Tradipitant inonzi neurokinin-1 (NK1) receptor antagonist yakagadzirwa naEli Lilly. Vanda akawana kodzero dzekusimudzira pasi rose dzeTradipitant kuburikidza nerezinesi muna Kubvumbi 2012.
Parizvino, Vanda yakagadzira Tradipitant yezviratidzo zvakaita seatopic dermatitis pruritus, gastroparesis, hutachiona hutsva hwekoronavirus, kurwara kwekufamba, kupindwa muropa nedoro, magariro phobia, uye indigestion.
Ichi Chidzidzo cheChikamu che3 chaisanganisira 316 varwere vane chirwere chekufamba vane nhoroondo yehutano hwekufamba, avo vakabatwa ne 170 mg Tradipitant, 85 mg Tradipitant, kana placebo panguva yerwendo rwechikepe.
Vese vakapinda muchidzidzo vaive nenhoroondo yekurwara negungwa. Mhedziso yekutanga yechidzidzo yaive mhedzisiro yetradipitant (170 mg) pakurutsa. Iwo akakosha echipiri ekupedzisira ndeaya: (1) mhedzisiro yetradipitant (85 mg) pakurutsa; (2) mhedzisiro yetradipitant mukudzivirira kusvotwa kwakanyanya uye kurutsa.
Zvinonzi chirwere chekufamba chinoramba chiri chidikanwi chekurapa chisingawanikwe. Iyo US Food and Drug Administration (FDA) haina kubvumidza mushonga mutsva wekurapa chirwere chekufamba kwemakore anopfuura makumi mana kubvira payakabvumidza scopolamine (chigamba chetransdermal chakaiswa kuseri kwenzeve) muna 1979.

Zvichienderana nedhata kubva kuzvidzidzo zviviri zveChikamu III, Vanda ichaendesa chikumbiro chekushambadzira chetradipitant kuFDA yekurapwa kwechirwere chekufamba muchikamu chechina cha2024.